-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
2026-03-11
Media Spotlight: Cangzhou Radio and Television Station | A New Chapter in Collaborative Development: Moving Forward with Innovation—Cangzhou Strives to Build a Premier Hub for the Pharmaceutical Industry
2026-02-19
China Pharmaceutical News 2026 Spring Festival Grassroots Visit | Greening the API Production Line
2026-01-28
Media Spotlight: Cangzhou Daily | Carbon Footprint Certification Opens the “Green Passport” to International Markets
Recently, Shijiazhuang Customs awarded Hebei Guangxiang Pharmaceutical Co., Ltd. the Certificate of Authorized Economic Operator (AEO) for Advanced Certification, making it the only pharmaceutical company in the province to obtain AEO status this year. This milestone signifies that the company has officially been recognized as an enterprise with the highest credit rating under customs supervision.
20
2025/12
During the 14th Five-Year Plan period, Cangzhou City has steadfastly regarded the construction of key projects as the cornerstone and powerful engine for high-quality development, making all-out efforts to ensure their successful implementation. This year, the city is undertaking 797 key construction projects with a total investment of RMB 477.12 billion, including 418 provincial- and municipal-level key projects. Recently, reporters visited several key project sites to gain firsthand insight into the city’s dynamic efforts to accelerate its transformation into a modern, coastal economic powerhouse by leveraging project development as a strategic driver.
17
2025/12
On December 10, Shijiazhuang Customs awarded the Advanced Authorized Economic Operator (AEO) Certificate to Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group (hereinafter referred to as “Guangxiang Pharmaceutical”), making it the only pharmaceutical company in the province to date this year to obtain AEO certification from Customs.
16
2025/12
On the morning of February 27, in the hematopoietic stem cell collection room of the Third Hospital of Hebei Medical University, a post-2000s young man successfully donated 395 milliliters of hematopoietic stem cell suspension after more than five hours of collection. These “seeds of life,” destined for recipients far away, carry with them profound love and the hope of renewed vitality. The young man is Lü Xiaolong, who works in the Warehousing Services Department of Hebei Guangxiang Pharmaceutical Co., Ltd., part of Shijiazhuang Sihua Pharmaceutical Group. He is also the second employee from the group to successfully donate hematopoietic stem cells.
13
2023/03
At present, Hebei Guangxiang Pharmaceutical Co., Ltd. has embarked on a journey to strive for the national-level “Little Giant” designation for specialized, refined, distinctive, and innovative enterprises. The company has identified untapped market opportunities and is poised to deepen its expertise in the niche area of specialty active pharmaceutical ingredients. Leveraging a suite of national, provincial, and municipal policies and initiatives supporting the development of the biopharmaceutical industry, the company is steadily increasing its R&D investment, continuously elevating its corporate performance, and achieving new leaps forward.
13
2022/11
Against the backdrop of implementing the nation’s new development philosophy and transitioning China from a major pharmaceutical producer to a leading pharmaceutical powerhouse, Shijiazhuang No.4 Pharmaceutical Group—one of China’s top 100 pharmaceutical companies (hereinafter referred to as “Shijiazhuang No.4”)—is vigorously pursuing a “API-plus-formulation” development strategy. Through strategic capital partnerships, acquisitions, and corporate restructuring, the company is actively expanding its upstream and downstream value chain, strengthening its competitiveness in both domestic and international markets, and injecting fresh momentum into the accelerated deployment and growth of its API business segment. A series of major initiatives are propelling Shijiazhuang No.4 Pharmaceutical Group toward its goal of becoming a leading API manufacturer.
23
2022/05
Its flagship product, caffeine, has seen robust growth across both production and sales; seven new specialty API products, including pentoxifylline and ornidazole, are poised for approval and market launch; and in the first quarter, its core business revenue posted triple-digit growth. Since the beginning of this year, Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has delivered a powerful “combination punch,” securing a strong start to its innovative development.
20
2022/04
Sharing feelings, recounting insights, and discussing the future... On November 23, in the Party and Mass Activities Room of Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, 20 Party members sat together, each taking turns to express their thoughts and experiences in studying the spirit of the Sixth Plenary Session of the 19th CPC Central Committee. The atmosphere was vibrant and enthusiastic, with everyone brimming with confidence about the future.
20
2022/01
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
Business License
